In this issue:
CAR T cell therapy shows promise in triple drug-class resistant RRMM
Serum BCMA may be prognostic for response and survival in MM
MM survivors have severe long-term sequelae including disability
No benefit to the addition of elotuzumab to a RVd regimen in high-risk patients
Achieving undetectable MRD mitigates the poor prognosis conferred by high-risk cytogenetics
Once-weekly dosing may be just as efficacious as twice-weekly KdD in the RR setting
Weekly administration of bortezomib for patients receiving front-line RVd
Autologous stem-cell collection following VTD or RVd induction
HORIZON demonstrates meaningful efficacy for melflufen in RRMM
TOP2A expression determines response to carfilzomib
Please login below to download this issue (PDF)